Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels

Ankit Dhiman, Charles C. Vining, Hunter D.D. Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K. Roggin, Mitchell C. Posner, Osmanuddin S. Ahmed, Stanley Liauw, Sean Pitroda, Chih Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blase Polite, Oliver S. Eng, Daniel V.T. Catenacci, Kiran K. Turaga

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: Metastatic adenocarcinomas of foregut origin are aggressive and have limited treatment options, poor quality of life, and a dismal prognosis. A subset of such patients with limited metastatic disease might have favorable outcomes with locoregional metastasis-directed therapies. This study investigates the role of sequential cytoreductive interventions in addition to the standard of care chemotherapy in patients with oligometastatic foregut adenocarcinoma. Methods: This is a single-center, phase II, open-label randomized clinical trial. Eligible patients include adults with synchronous or metachronous oligometastatic (metastasis limited to two sites and amenable for curative/ablative treatment) adenocarcinoma of the foregut without progression after induction chemotherapy and having undetectable ctDNA. These patients will undergo induction chemotherapy and will then be randomized (1:1) to either sequential curative intervention followed by maintenance chemotherapy versus routine continued chemotherapy. The primary endpoint is progression-free survival (PFS), and a total of 48 patients will be enrolled to detect an improvement in the median PFS in the intervention arm with a hazard ratio (HR) of 0.5 with 80% power and a one-sided alpha of 0.1. Secondary endpoints include disease-free survival (DFS) in the intervention arm, overall survival (OS), ctDNA conversion rate pre/post-induction chemotherapy, ctDNA PFS, PFS2, adverse events, quality of life, and financial toxicity. Discussion: This is the first randomized study that aims to prospectively evaluate the efficacy and safety of surgical/ablative interventions in patients with ctDNA-negative oligometastatic adenocarcinoma of foregut origin post-induction chemotherapy. The results from this study will likely develop pertinent, timely, and relevant knowledge in oncology.

Original languageEnglish (US)
Pages (from-to)4583-4592
Number of pages10
JournalAnnals of Surgical Oncology
Volume29
Issue number7
DOIs
StatePublished - Jul 2022

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels'. Together they form a unique fingerprint.

Cite this